DaraxonrasibelironrasibpembrolizumabNSCLCanti-PD-1 immunotherapyimmunotherapy
… cancer (NSCLC) where immunotherapy is standard of care.Methods Daraxonrasib, a RAS(ON) multi-selective inhibitor, and elironrasib, a RAS(ON…
3articles mentioning drugs
6drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: daraxonrasib ×
daraxonrasib
This drug is selected. Its supporting articles are shown below.
Articles mentioning daraxonrasib
3 articles · page 1 of 1pembrolizumab5-fluorouracilleucovorinadagrasibzenocutuzumabliposomal irinotecandaraxonrasibPancreatic ductal adenocarcinoma (PDAC)NAPOLI-1 trialconventional chemotherapy
…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…
AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…